Genomic and Molecular Biomarker Testing for Cancer



Original Effective Date: 08/05/2025 Effective Date: 01/07/2026 Review Date: 08/05/2025 Policy Number: HUM-2248-000 Line of Business: Medicaid

States: Ohio

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Table of Contents				
Category	Tests			
Hematologic Malignancies and Suspected Myeloid Disorders - Comprehensive Genomic Profiling/Multigene Panel Testing	 Augusta Hematology Optical Genome Mapping DH Optical Genome Mapping/Digital Karyotyping Assay 			
Hematologic Malignancies and Suspected Myeloid Disorders – Single Gene Testing	• ASXL1 • EZH2			
Solid Tumors - Comprehensive Genomic Profiling	 Comprehensive genomic profiling ExaCT-1 Whole Exome Testing Guardant360 Tissue Next MSK-IMPACT Oncomap ExTra Oncotype MAP PanCancer Tissue Test PGDx elio tissue complete 			

Scope

This policy applies to all physical and behavioral health prior authorization requests received by Humana Healthy Horizons in Ohio.

Policy

Humana Healthy Horizons in Ohio uses established criteria guidelines to make medical necessity decisions and follows the below procedure. Decisions are made on a case-by-case basis, utilizing the information provided about the member's health status and an assessment of the local delivery system. Emergent services do not require a referral or preauthorization.

The Plan covers all benefits and services required in Ohio Administrative Code (OAC) chapter 5160 in the amount, duration, and scope for the same services furnished to members under the fee-for-service (FFS) Medicaid.

When the plan receives a request for a primary code that requires prior authorization and the primary code is denied for lack of medical necessity, any related secondary codes submitted on the authorization request will be denied based on lack of medical necessity. When a primary code is approved, related secondary codes requiring prior authorization will be reviewed individually for medically necessity determinations.

Please see Ohio Medicaid Prior Authorization and Notification List for a list of CPT and HCPCS codes that require prior authorization.

Humana Healthy Horizons in Ohio will review requested non-MCO covered codes and services as required for Early and Periodic Screening, Diagnostic and Treatment (EPSDT) for medical necessity to ensure children and adolescents receive appropriate and preventative, dental, mental health, developmental and specialty services.

Humana Healthy Horizons in Ohio does not cover services, items or devices that have not been approved by the Food and Drug Administration (FDA). Other factors affecting reimbursement supersede this policy. These factors include but are not limited to Federal and/or State statutes and regulations, the State Plan, the MCE Manual, physician or other provider contracts, the beneficiaries' benefit coverage documents, and/or other reimbursement, medical or drug policies.

Providers may submit authorization request(s) through the provider portal. A provider may request an urgent prior authorization in situations where the provider considers a delay in providing services, supplies or prescription drugs requiring prior authorization to be detrimental to the health of the member. The absence of authorization and/or notification prior to the date of a service could result in financial penalties for the practice and reduced benefits for the member, based on the healthcare provider's contract and the member's Certificate of Coverage. Services or medications provided without preauthorization may be subject to retrospective medical necessity review. We recommend individual practitioners making specific requests for services or medications verify benefits and preauthorization requirements with Humana prior to providing services.

Medical necessity documentation and rationale must be submitted with the prior authorization request. Providers may access physical and behavioral clinical coverage policies and medical necessity criteria at the below links.

Physical Health:

www.humana.com/provider/medical-resources/ohio-medicaid/physical-health-clinical-coverage-policies

Behavioral Health:

www.humana.com/provider/medical-resources/ohio-medicaid/behavioral-health-clinical-coverage-policies

Members may request a copy of the medical necessity criteria by calling member services at 877-856-5702 (TTY:711), Monday-Friday, 7AM to 8PM EST.

Providers may request a copy of the medical necessity criteria by calling provider services at 877-856-5707 (TTY:711), Monday-Friday, 7AM to 8PM EST or emailing the request to ODMCDUM@humana.com.

Procedures

- 1. The Plan uses the following hierarchy of guidelines to review for medical necessity:
 - 1.1 Federal or state regulation, including medical criteria published in the Ohio Administrative Code, Chapter 5160.
 - 1.2 Nationally accepted evidence based clinical guidelines: MCG (formerly Milliman Care Guidelines), American Society of Addiction Medicine (ASAM) Level of Care Adolescent Guidelines and American Society of Addiction Medicine (ASAM) Patient Placement Criteria (ASAM Admission Guidelines).
 - 1.3 Humana Healthy Horizons™ in Ohio clinical policies
 - 1.4 In the case of no guidance from above, additional information that the clinical reviewer will consider, when available, includes;
 - 1.4.1 Clinical practice guidelines and reports from peer reviewed medical literature, from which a higher level of evidence and study quality is more strongly considered in determinations;
 - 1.4.2 Professional standards for safety and effectiveness recognized in the US for diagnosis, care, or treatment;
 - 1.4.3 Medical association publications;
 - 1.4.4 Government-funded or independent entities that assess and report on clinical care; Decision and technology such as Agency for Healthcare Research and Quality (AHRQ), Hayes Technology Assessment, Up-To-Date, Cochrane Reviews, National Institute for Health and Care Excellence (NICE), etc.;
 - 1.4.5 Published expert opinions;
 - 1.4.6 Opinion of health professionals in the area of specialty involved;
 - 1.4.7 Opinion of attending provider;
 - 1.5 Dental: DentaQuest coverage guidelines and policies

 Dental Coverage Humana Healthy Horizons in Ohio | Humana
 - 1.6 Vision: EyeMed coverage guidelines and policies
 Vision Care Humana Healthy Horizons Ohio Medicaid | Humana

HEMATOLOGIC MALIGNANCIES AND SUSPECTED MYELOID DISORDERS Comprehensive Genomic Profiling/Multigene Panel Testing

Description

Comprehensive genomic profiling (CGP) (also referred to as comprehensive molecular profiling) is a type of test that involves a combination of laboratory methodologies to detect genetic alterations and biomarkers in blood or bone marrow to aid in the management of hematologic malignancies and suspected myeloid disorders. Testing is performed by removing a small sample of tissue for evaluation (eg, bone marrow biopsies, bone marrow aspirates, bone marrow clots), blood draw (peripheral blood samples), or sites located outside of the bone marrow (extramedullary) suspected of harboring a myeloid malignancy. Techniques can vary from test to test and may include but are not limited to, next-generation sequencing (NGS), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Examples of CGP tests include, but are not limited to, FoundationOne Heme and Neogenomics myeloid and/or heme panels.

Optical genome mapping (OGM) is a laboratory technique used to analyze long stretches of DNA allowing a broad view of the genome to detect large structural variations. This type of test may be able to detect changes that other assays may miss such as deletions, duplications, insertions, inversions and translocations. OGM has been proposed for use in hematologic malignancies and include tests such as Augusta Hematology Optical Genome Mapping and DH Optical Genome Mapping/Digital Karyotyping Assay.

Coverage Determination

<u>Comprehensive Genomic Profiling or Multigene Panel Testing for Hematologic Malignancies and</u> Suspected Myeloid Disorders

Humana members may be eligible under the Plan for comprehensive genomic profiling or multigene panel testing (81450, 81455, 81456) for any of the following indications:

- Cancer of the blood and bone marrow (eg, acute myelogenous leukemia [AML])¹⁴; OR
- Myelodysplastic syndrome (MDS)¹⁵; OR
- Myeloproliferative neoplasms (MPNs) which include polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF)¹⁶, OR
- Suspected myeloid malignancy (does not have a diagnosis of cancer) with <u>undefined cytopenia</u>* for greater than four months without a known cause¹³; OR
- Systemic mastocytosis¹⁸

^{*}Clinical, laboratory and pathologic assessment are nondiagnostic (such as demonstration of persistent cytopenias [eg, four months] by complete blood count, microscopic examination of a bone marrow biopsy

and bone marrow cytogenetic studies. Other than the clinical feature of the number of cytopenias and specific cytogenetic changes found recurrently in myelodysplastic syndrome [MDS], all other diagnostic criteria in MDS rely upon light microscopy findings).¹³

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **optical genome mapping (81195)** including, but not limited to:

- Augusta Hematology Optical Genome Mapping (0331U)
- DH Optical Genome Mapping/Digital Karyotyping Assay (0413U)

A review of the current medical literature shows that there is **no evidence** to determine that these services are standard medical treatments. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT [®] Code(s)	Description	Comments
81450	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA	
81455	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA an	
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA an	
CPT® Category III Code(s)	Description	Comments

No code(s) identified				
HCPCS Code(s)	Description	Comments		
No code(s) identified				

References

- 1. American Society of Addiction Medicine. https://asam.org.
- 2. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
- 3. Association for Molecular Pathology (AMP). Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the Association for Molecular Pathology. https://amp.org. Published November 2018.
- 4. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J*. 2018; 8(2):15.
- 5. ClinicalKey. Clinical Overview. Acute myelogenous leukemia. https://clinicalkey.com. Updated March 10, 2025.
- 6. ClinicalKey. Clinical Overview. Myelodysplastic syndrome. https://clinicalkey.com. Updated January 1, 2025.
- 7. College of American Pathologists (CAP). CAP Laboratory Improvement Programs. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. https://cap.org. Published October 2017.
- 8. Hayes, Inc. Clinical Utility Evaluation. Genetic testing for the diagnosis and treatment of polycythemia vera (PV). https://evidence.hayesinc.com. Published April 2, 2018. Updated June 17, 2022.
- 9. Hayes, Inc. Clinical Utility Evaluation. Genetic testing for the diagnosis and treatment monitoring of primary myelofibrosis (PMF). https://evidence.hayesinc.com. Published April 12, 2018. Updated June 17, 2022.
- 10. Hayes, Inc. GTE Report. Molecular/cytogenetic testing for diagnosis and prognosis in primary/de novo acute myeloid leukemia (AML). https://evidence.hayesinc.com. Published July 24, 2014. Updated July 7, 2015.

- 11. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
- 12. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood*. 2017;129(25):3371-3378.
- 13. MCG Health. https://humana.access.mcg.com/index.
- 14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. https://nccn.org. Updated January 27, 2025.
- 15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. https://nccn.org. Updated January 17, 2025.
- 16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms. https://nccn.org. Updated February 21, 2025.
- 17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic mastocytosis. https://nccn.org. Updated February 21, 2025.
- 18. Ohio Administrative Code Chapter 5160 Ohio Department of Medicaid. <u>Chapter 5160 Ohio Administrative Code</u> | Ohio Laws.
- 19. Ohio Administrative Code 5160-1-01 Medicaid medical necessity: definitions and principles. <u>Rule 5160-1-01 Ohio Administrative Code | Ohio Laws</u>.
- 20. Ohio Administrative Code 5160-26-01 Managed care: definitions. Rule 5160-26-01 Ohio Administrative Code | Ohio Laws.
- 21. UpToDate, Inc. Acute myeloid leukemia: clinical manifestations, pathologic features, and diagnosis. https://uptodate.com. Updated May 2025.
- 22. UpToDate, Inc. Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS). https://uptodate.com. Updated May 2025.
- 23. UpToDate, Inc. General aspects of cytogenetic analysis in hematologic malignancies. https://uptodate.com. Updated May 2025.
- 24. Yu J, Li Y, Li T, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. *Exp Hematol Oncol*. 2020;9:2.
- 25. Zheng G, Chen P, Pallavajjalla A, et al. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. *Am J Hematol*. 2019;94(10):1141-1148.

HEMATOLOGIC MALIGNANCIES AND SUSPECTED MYELOID DISORDERS Single Gene Testing

Description

Single gene testing may also be performed for hematologic malignancies and suspected myeloid disorders and may be indicated for an individual who exhibits disease symptoms and may be necessary to diagnose or rule out suspected cancer or monitor known cancer. These include, but are not limited to, *ASXL1*, *BTK*, *CCND1*, *CEBPA*, *EZH2*, *IDH1*, *IDH2*, *MYD88*, *NPM1*, *PLCG2*, *RUNX1*, *SF3B1*, *SRSF2*, *U2AF1*, and *ZRSR2*.

Coverage Determination

ASXL1 Gene Testing

Humana members may be eligible under the Plan for **ASXL1** gene testing (81175/81176) for any of the following indications:

- AML (includes acute promyelocytic leukemia [APL]); OR
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN); OR
- Chronic myeloid leukemia (CML) ¹⁴; OR
- Myelodysplastic syndrome (MDS); OR
- Myeloproliferative neoplasms (MPN); OR
- Suspected myeloid malignancy with <u>undefined cytopenia</u>*; OR
- Systemic mastocytosis

EZH2 Gene Testing

Humana members may be eligible under the Plan for *EZH2* gene testing (81237) for any of the following indications:

- AML (includes APL); OR
- Diffuse large b-cell lymphoma; OR
- Follicular lymphoma to determine benefit of treatment with tazemetostat (Tazverik) performed with an FDA-approved test; **OR**
- MDS; OR
- MPNs

Coverage Limitations

There are no limitations; refer to Coverage Determination Section.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT®	Description	Comments
Code(s)	Description	Comments
81175	ASXL1 (additional sex combs like 1, transcriptional regulator)	
	(eg, myelodysplastic syndrome, myeloproliferative neoplasms,	
	chronic myelomonocytic leukemia), gene analysis; full gene	
	sequence	
	ASXL1 (additional sex combs like 1, transcriptional regulator)	
81176	(eg, myelodysplastic syndrome, myeloproliferative neoplasms,	
	chronic myelomonocytic leukemia), gene analysis; targeted	
	sequence analysis (eg, exon 12)	
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2	
	subunit) (eg, diffuse large B-cell lymphoma) gene analysis,	
	common variant(s) (eg, codon 646)	
CPT®		
Category III	Description	Comments
Code(s)		
No code(s) identified		
HCPCS	Description	Comments
Code(s)	Description	Comments
No code(s) identified		

References

- 1. American Society of Addiction Medicine. https://asam.org.
- 2. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
- 3. MCG Health.https://humana.access.mcg.com/index.

- 4. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium. ASXL1, EZH2. https://nccn.org. Updated 2025.
- 5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. https://nccn.org. Updated June 27, 2025.
- 6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. https://nccn.org. Updated January 27, 2025.
- 7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. https://nccn.org. Updated February 10, 2025.
- 8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. https://nccn.org. Updated April 2, 2025.
- 9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic myeloid leukemia. https://nccn.org. Updated November 27, 2024.
- 10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. https://nccn.org. Updated June 24, 2025.
- 11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. https://nccn.org. Updated January 17, 2025.
- 12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms. https://nccn.org. Updated February 21, 2025.
- 13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic light chain amyloidosis. https://nccn.org. Updated June 11, 2025.
- 14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic mastocytosis. https://nccn.org. Updated February 21, 2025.
- 15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. https://nccn.org. Updated June 24, 2025.
- 16. Ohio Administrative Code Chapter 5160 Ohio Department of Medicaid. <u>Chapter 5160 Ohio Administrative Code</u> | Ohio Laws.
- 17. Ohio Administrative Code 5160-1-01 Medicaid medical necessity: definitions and principles. <u>Rule 5160-1-01 Ohio Administrative Code | Ohio Laws</u>.
- 18. Ohio Administrative Code 5160-26-01 Managed care: definitions. Rule 5160-26-01 Ohio Administrative Code | Ohio Laws.

- 19. US Food & Drug Administration (FDA). Full prescribing information: Tazverik (tazemetostat). https://fda.gov. Published 2020. Updated August 2024.
- 20. US Food & Drug Administration (FDA). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). https://fda.gov. Updated March 5, 2025.
- 21. US Food & Drug Administration (FDA). Premarket approval. cobas EZH2 Mutation Test. https://fda.gov. Published June 22, 2020.

SOLID TUMORS

Comprehensive Genomic Profiling and Multigene Panel Testing

Description

Comprehensive genomic profiling (CGP) (also referred to as comprehensive molecular profiling or tumor profiling) is a laboratory diagnostic method used to analyze the genetic makeup of solid tumors. CGP examines a wide range of genetic variations including mutations, insertions, deletions, amplifications and rearrangements across hundreds of genes. CGP can help guide targeted treatment options. Some CGP tests analyze DNA to detect genetic alterations. These DNA-based tests focus on identifying somatic mutations which occur in tumor cells and are not inherited. Examples include, but are not limited to, Guardant360 TissueNext, MSK-IMPACT, Oncotype MAP Pan-Cancer Tissue Test and PGDx elio tissue complete.

Optical genome mapping, transcriptome, whole exome sequencing (WES) and whole genome sequencing (WGS) are other laboratory methods that have been proposed to profile tumors. These techniques purportedly identify genetic variants in an individual's cancer cells to potentially identify actionable genomic mutations to assist with selection of targeted therapies to treat cancer. Examples include, but are not limited to, EXaCT-1 Whole Exome Sequencing, Praxis Somatic Combined Whole Genome Sequencing and Optimal Genome Mapping, Praxis Somatic Transcriptome and Praxis Somatic Whole Genome Sequencing.

Coverage Determination

Comprehensive Genomic Profiling

Humana members may be eligible under the Plan for **comprehensive genomic profiling for solid tumors** (81455, 81456) for any of the following tests when the criteria below are met:

- ExaCT-1 Whole Exome Testing; OR
- Guardant360 Tissue Next; OR
- MSK-IMPACT; OR
- Oncotype MAP PanCancer Tissue Test; OR
- Oncomap ExTra; OR
- PGDx elio tissue complete;

AND both of the following:

- Individual to be tested has been diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; AND
- o Individual has decided to seek further cancer treatment (eg, therapeutic chemotherapy)

Coverage Limitations

There are no limitations; refer to Coverage Determination Section.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT®	Decemention	Commonts
Code(s)	Description	Comments
81455	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA an	
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA an	
CPT®		
Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Society of Addiction Medicine. https://asam.org.

- 2. American Academy of Dermatology (AAD). Guidelines of care for the management of primary cutaneous melanoma. https://aad.org. Published January 2019.
- 3. American College of Medical Genetics and Genomics (ACMG). ACMG Technical Standard. Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: cytogenomic studies of acquired chromosomal abnormalities in solid tumors. https://acmg.net. Published 2024.
- 4. American Society of Clinical Oncology (ASCO). Biomarkers for systemic therapy in metastatic breast cancer guideline and rapid update. https://asco.org. Updated February 6, 2024.
- 5. American Society of Clinical Oncology (ASCO). Endocrine treatment and targeted therapy for HR-positive, HER2-negative metastatic breast cancer guideline and rapid update. https://asco.org. Published February 22, 2016. Updated February 18, 2025.
- 6. American Society of Clinical Oncology (ASCO). Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. https://asco.org. Published January 9, 2025.
- 7. American Society of Clinical Oncology (ASCO). Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. https://asco.org. Published December 15, 2022.
- 8. American Society of Clinical Oncology (ASCO). Metastatic pancreatic cancer: ASCO guideline update. https://asco.org. Published August 5, 2020.
- 9. American Society of Clinical Oncology (ASCO). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. https://asco.org. Published January 5, 2023.
- 10. American Society of Clinical Oncology (ASCO). Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology clinical practice guideline update. https://asco.org. Published February 5, 2018.
- 11. American Society of Clinical Oncology (ASCO). Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. https://asco.org. Published August 25, 2022.
- American Society of Clinical Oncology (ASCO). Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. https://asco.org. Published February 10, 2022. Updated February 24, 2025.
- 13. American Society of Clinical Oncology (ASCO). Treatment of metastatic colorectal cancer: ASCO guideline. https://asco.org. Published October 17, 2022.

- 14. American Society of Clinical Oncology (ASCO). Treatment of pleural mesothelioma: ASCO guideline update. https://asco.org. Published January 8, 2025.
- 15. American Thyroid Association (ATA). 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. https://thyroid.org. Published 2021.
- 16. American Thyroid Association (ATA). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. https://thyroid.org. Published 2015.
- 17. American Urological Association (AUA). Advanced prostate cancer: AUA/SUO guideline. https://auanet.org. Published 2020. Updated 2023.
- 18. Association for Molecular Pathology (AMP). Molecular biomarkers for the evaluation of colorectal cancer. https://amp.org. Published March 2017.
- 19. Association for Molecular Pathology (AMP). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. https://amp.org. Published March 2013.
- 20. College of American Pathologists (CAP). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy statements and strengths of recommendations: guideline From the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. https://cap.org. Published August 3, 2022.
- 21. College of American Pathologists (CAP). Molecular biomarker testing for the diagnosis of diffuse gliomas: guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology. https://cap.org. Published May 2022.
- 22. College of American Pathologists (CAP). Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. https://cap.org. Published May 2017.
- 23. Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. *JCO Precis Oncol.* 2018:2:PO.18.00169.
- 24. Hayes, Inc. Precision Medicine Research Brief. Guardant360 TissueNext (Guardant Health Inc.). https://evidence.hayesinc.com. Published May 3, 2023.
- 25. MCG Health.https://humana.access.mcg.com/index.
- 26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Biliary tract cancers. https://nccn.org. Updated January 10, 2025.

- 27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. https://nccn.org. Updated January 17, 2025.
- 28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. https://nccn.org. Updated April 17, 2025.
- 29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Central nervous system cancers. https://nccn.org. Updated January 21, 2025.
- 30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. https://nccn.org. Updated January 31, 2025.
- 31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer. https://nccn.org. Updated April 24, 2025.
- 32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. https://nccn.org. Updated December 20, 2024.
- 33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Gastric cancer. https://nccn.org. Updated December 20, 2024.
- 34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Gastrointestinal stromal tumors. https://nccn.org. Updated July 31, 2024.
- 35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal, endometrial, and gastric. https://nccn.org. Updated October 31, 2024.
- 36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. https://nccn.org. Updated January 17, 2025.
- 37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatocellular carcinoma. https://nccn.org. Updated January 10, 2025.
- 38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: cutaneous. https://nccn.org. Updated January 28, 2025.
- 39. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Neuroblastoma. https://nccn.org. Updated July 2, 2024.
- 40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and adrenal tumors. https://nccn.org. Updated January 17, 2025.

- 41. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. https://nccn.org. Updated January 14, 2025.
- 42. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Occult primary (cancer of unknown primary [CUP]). https://nccn.org. Updated September 11, 2024.
- 43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. https://nccn.org. Updated July 16, 2025.
- 44. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. https://nccn.org. Updated December 20, 2024.
- 45. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. https://nccn.org. Updated December 4, 2024.
- 46. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer. https://nccn.org. Updated March 31, 2025.
- 47. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. https://nccn.org. Updated January 15, 2025.
- 48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. https://nccn.org. Updated March 7, 2025.
- 49. Ohio Administrative Code Chapter 5160 Ohio Department of Medicaid. <u>Chapter 5160 Ohio Administrative Code</u> | Ohio Laws.
- 50. Ohio Administrative Code 5160-1-01 Medicaid medical necessity: definitions and principles. Rule 5160-1-01 Ohio Administrative Code | Ohio Laws.
- 51. Ohio Administrative Code 5160-26-01 Managed care: definitions. Rule 5160-26-01 Ohio Administrative Code | Ohio Laws.
- 52. Rennert H, Eng K, Zhang T, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. *NPJ Genom Med*. 2016;1: 16019.
- 53. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. https://sitcancer.org. Published August 13, 2021.
- 54. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. https://sitcancer.org. Published June 7, 2023.

- 55. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. https://sitcancer.org. Published June 9, 2023.
- 56. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. https://sitcancer.org. Published May 31, 2022.
- 57. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. https://sitcancer.org. Published October 18, 2023.
- 58. UpToDate, Inc. Adenocarcinoma of unknown primary site. https://uptodate.com. Updated January 2025.
- 59. UpToDate, Inc. Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors. https://uptodate.com. Updated January 2025.
- 60. UpToDate, Inc. Anaplastic thyroid cancer. https://uptodate.com. Updated January 2025.
- 61. UpToDate, Inc. Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors. https://uptodate.com. Updated January 2025.
- 62. UpToDate, Inc. Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas. https://uptodate.com. Updated January 2025.
- 63. UpToDate, Inc. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors. https://uptodate.com. Updated January 2025.
- 64. UpToDate, Inc. Initial systemic therapy for advanced non-small cell lung cancer lacking a driver mutation. https://uptodate.com. Updated January 2025.
- 65. UpToDate, Inc. Initial systemic therapy for metastatic colorectal cancer. https://uptodate.com. Updated January 21, 2025.
- 66. UpToDate, Inc. Initial systemic therapy for metastatic esophageal and gastric cancer. https://uptodate.com. Updated January 2025.
- 67. UpToDate, Inc. Initial systemic therapy for metastatic exocrine pancreatic cancer. https://uptodate.com. Updated January 25, 2025.
- 68. UpToDate, Inc. Malignant salivary gland tumors: treatment of recurrent and metastatic disease. https://uptodate.com. Updated January 2025.

- 69. UpToDate, Inc. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. https://uptodate.com. Updated January 2025.
- 70. UpToDate, Inc. Management of glioblastoma in older adults. https://uptodate.com. Updated January 21, 2025.
- 71. UpToDate, Inc. Management of ovarian cancer associated with BRCA and other genetic mutations. https://uptodate.com. Updated January 2025.
- 72. UpToDate, Inc. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: platinum-resistant disease. https://uptodate.com. Updated January 2025.
- 73. UpToDate, Inc. Medullary thyroid cancer: systemic therapy and immunotherapy. https://uptodate.com. Updated January 2025.
- 74. UpToDate, Inc. Melanoma: clinical features and diagnosis. https://uptodate.com. Updated January 2025.
- 75. UpToDate, Inc. Metastatic uveal melanoma. https://uptodate.com. Updated January 2025.
- 76. UpToDate, Inc. Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer. https://uptodate.com. Updated January 2025.
- 77. UpToDate, Inc. Overview of advanced unresectable and metastatic solid tumors with DNA mismatch repair deficiency or high tumor mutational burden. https://uptodate.com. Updated January 2025.
- 78. UpToDate, Inc. Overview of the approach to metastatic breast cancer. https://uptodate.com. Updated January 2025.
- 79. UpToDate, Inc. Overview of the classification and management of cancers of unknown primary site. https://uptodate.com. Updated January 2025.
- 80. UpToDate, Inc. Overview of the initial treatment of advanced non-small cell lung cancer. https://uptodate.com. Updated January 2025.
- 81. UpToDate, Inc. Overview of the management of advanced cutaneous melanoma. https://uptodate.com. Updated January 2025.
- 82. UpToDate, Inc. Pathology and prognostic determinants of colorectal cancer. https://uptodate.com. Updated January 2025.
- 83. UpToDate, Inc. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. https://uptodate.com. Updated January 22, 2025.

- 84. UpToDate, Inc. Poorly differentiated cancer from an unknown primary site. https://uptodate.com. Updated January 2025.
- 85. UpToDate, Inc. Principles of cancer immunotherapy. https://uptodate.com. Updated January 2025.
- 86. UpToDate, Inc. Prognostic and predictive factors in metastatic breast cancer. https://uptodate.com. Updated August 2024.
- 87. UpToDate, Inc. Second- and later-line systemic therapy for metastatic exocrine pancreatic cancer. https://uptodate.com. Updated January 31, 2025.
- 88. UpToDate, Inc. Second and later lines of therapy for metastatic soft tissue sarcoma. https://uptodate.com. Updated January 2025.
- 89. UpToDate, Inc. Systemic therapy for advanced unresectable and metastatic cholangiocarcinoma. https://uptodate.com. Updated January 2025.
- 90. UpToDate, Inc. Systemic treatment of metastatic melanoma with BRAF and other molecular alterations. https://uptodate.com. Updated January 2025.
- 91. UpToDate, Inc. Treatment of advanced unresectable and metastatic gallbladder cancer. https://uptodate.com. Updated January 2025.
- 92. UpToDate, Inc. Treatment for hormone receptor-positive, HER2-negative advanced breast cancer. https://uptodate.com. Updated January 31, 2025.
- 93. UpToDate, Inc. Treatment of metastatic breast cancer in older women. https://uptodate.com. Updated August 2024.
- 94. UpToDate, Inc. Treatment of metastatic urothelial cancer of the bladder and urinary tract. https://uptodate.com. Updated January 7, 2025.
- 95. UpToDate, Inc. TRK fusion-positive cancers and TRK inhibitor therapy. https://uptodate.com. Updated January 8, 2025.
- 96. UpToDate, Inc. Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors. https://uptodate.com. Updated January 2025.
- 97. US Food & Drug Administration (FDA). 510(k) premarket approval: PGDx elio tissue complete. https://fda.gov. Published April 24, 2020.
- 98. US Food & Drug Administration (FDA). De novo summary: MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). https://fda.gov. Published November 15, 2017.

99. US Food & Drug Administration (FDA). Premarket approval. Oncomine Dx Target Test. https://fda.gov. Published June 22, 2017. Updated October 2024.

Definitions

- 1. Adverse Benefit Determination As defined in OAC rule 5160-26-01, is a managed care entity's (MCEs):
 - Denial or limited authorization of a requested service, including determinations based on the type or level of service, requirements for medical necessity, appropriateness, setting, or effectiveness of a covered benefit;
 - 2) Reduction, suspension, or termination or services prior to the member receiving the services previously authorized by the MCE;
 - 3) Failure to provide services in a timely manner as specified in rule 5160-26-03.1 of the Administrative Code;
 - 4) Failure to act within the resolution timeframes specified in rule 5160-26-08.4 of the Administrative Code;
 - 5) Denial of a member's request to dispute a financial liability, including cost sharing, copayments, premiums, deductibles, coinsurance, and other member financial liabilities, if applicable; or
 - 6) Denial, in whole or part, of payment for a service. A denial, in whole or in part, of a payment for a service solely because the claim does not meet the definition of a "clean claim" as defined in 42 C.F.R. 447.45(b) (October 1, 2021) is not an adverse benefit determination).
- 2. American Society of Addiction Medicine (ASAM) a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM produces a comprehensive set of standards for placement, continued stay, transfer or discharge of patients with addiction and co-occurring conditions used by clinical staff to determine whether to refer a service request for physician review based upon the clinical information submitted by the requestor.
- 3. MCG are nationally recognized guidelines used by clinical staff to determine whether to refer a service request for physician review based upon the clinical information submitted by the requestor.
- 4. Medically Necessary or Medical Necessity Has the same meaning as OAC rule 5160-1-01:
 - A. Medical necessity for individuals covered by early and periodic screening, diagnosis, and treatment (EPSDT) is criteria of coverage for procedures, items, or services that prevent, diagnose, evaluate, correct, ameliorate, or treat as adverse health condition such as an illness, injury, disease or its symptoms, emotional or behavioral dysfunction, intellectual deficit, cognitive impairment, or developmental disability.
 - B. Medical necessity for individuals not covered by EPSDT is criteria of coverage for procedures, items, or services that prevent, diagnose, evaluate or treat an adverse health condition such as an illness, injury, disease or its symptoms, emotional or behavioral dysfunction, intellectual deficit, cognitive impairment, or developmental disability and without which the person can be expected to suffer prolonged, increased, or new morbidity; impairment of function; dysfunction of a body organ or part; or significant pain and discomfort.
 - C. Conditions of medical necessity for a procedure, item, or service are met all the following apply:
 - 1) It meets generally accepted standards of medical practice;
 - 2) It is clinically appropriate in its type, frequency, extent, duration, and delivery setting;

Genomic and Molecular Biomarker Testing for Cancer

Page: 21 of 21

- 3) It is appropriate to the adverse health condition for which it is provided and is expected to produce the desired outcome;
- 4) It is the lowest cost alternative that effectively addresses and treats the medical problem;
- 5) It provides unique, essential, and appropriate information if it is used for diagnostic purposes; and
- 6) It is not provided primarily for the economic benefit of the provider nor for the sole convenience of the provider or anyone else other than the recipient.
- D. The fact that a physician, dentist, or other licensed practitioner renders, prescribes, orders, certifies, recommends, approves, or submits a claim for a procedure, item, or service does not, in and of itself make the procedure, item, or service medically necessary and does not guarantee payment.
- E. The definition and conditions of medical necessity articulated in this rule apply throughout the entire medicaid program. More specific criteria regarding the conditions of medical necessity for particular categories of service may be set forth within the Ohio Department of Medicaid (ODM) coverage policies or rules.

Change Summary

08/05/2025 New Policy.